Merck hit hard by cholesterol drug rejection
NEW YORK (Reuters) - Confidence in Merck & Co's earnings prospects withered on Tuesday, along with its stock price, after U.S. regulators surprisingly rejected the drugmaker's treatment to raise levels of "good" HDL cholesterol.
<p><img src="http://feeds.reuters.com/~a/reuters/businessNews?i=ZhV63n" border="0"></img> (http://feeds.reuters.com/~a/reuters/businessNews?a=ZhV63n)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/businessNews?i=w0bbcG" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=w0bbcG) <img src="http://feeds.reuters.com/~f/reuters/businessNews?i=Kl5Mag" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=Kl5Mag) <img src="http://feeds.reuters.com/~f/reuters/businessNews?i=SHn3tg" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=SHn3tg)
</div><img src="http://feeds.reuters.com/~r/reuters/businessNews/~4/280169645" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/businessNews/~3/280169645/idUSN2931579520080429